Article

Intravitreal bevacizumab for myopic choroidal neovascularization.

Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
Ophthalmic Surgery Lasers and Imaging (impact factor: 0.62). 39(3):182-5. pp.182-5
Source: PubMed

ABSTRACT To evaluate the effect of intravitreal bevacizumab on visual acuity in patients with myopic choroidal neovascularization.
The retrospective case series study included 13 patients with myopic choroidal neovascularization who received three intravitreal injections of 1.5 mg of bevacizumab.
At 1, 3, and 6 months after the first injection, mean visual acuity improved significantly from 0.63 +/- 0.41 logarithm of the minimum angle of resolution units (LogMAR) to 0.39 +/- 0.22 (P< .001), 0.47 +/- 0.49 (P= .002), and 0.52 +/- 0.49 LogMAR (P = 0.009), respectively. The increase in visual acuity was correlated with a significant decrease in central retinal thickness (P = .003) as measured by optical coherence tomography. Mean intraocular pressure did not change significantly (P> .05) during follow-up.
Intravitreal injections of bevacizumab may be a therapeutic option for exudative myopic macular degeneration.

0 0
 · 
0 Bookmarks
 · 
29 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

6 months
 
central retinal thickness
 
Intravitreal injections
 
LogMAR
 
Mean intraocular pressure
 
minimum angle
 
myopic choroidal neovascularization
 
optical coherence tomography
 
retrospective case series study
 
therapeutic option
 
visual acuity